1 |
V. Angela, C. Traino, B. Giuseppeb, G. Marianob, L. Patriziab, C. Chiarac, D. Maria Vittoriad, F. Giorgiod, L. Mauroa, M. Giulianob, F. Marcoe "Comparison between remnant and red-marrow absorbed dose in thyroid cancer patients submitted to 131I ablative therapy after rh-TSH stimulation versus hypothyroidism induced by L-thyroxine withdrawal." Nuclear Medicine Communications, Vol. 28, No. 3, pp. 215-23, 2007.
DOI
|
2 |
B. Aschebrook-Kilfoy, M. H. Ward, M. M. Sabra, S. S. Devesa. "Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006." Vol. 21, No. 2, pp. 125-34, 2011.
DOI
|
3 |
United States Nuclear Regulatory Commission Office of Federal and State Material and Environmental Management Programs 2009 Washington, DC: 20555-0001. NRC Information Notice 2003-22, Supplement 2009.
|
4 |
Nuclear Safety Commission No. 19 Regulations on Technical Standards such as Radiation Safety Management. Nuclear Safety Commission Notification No. 2015-5 Technical Standards on Radiation Safety Management in the Medical Sector
|
5 |
K. H. Yi, E. K. Lee, H. C. Kang, Y. W. Koh, S. W. Kim, I. J. Kim, D. G. Na, K. H. Nam, S. Y. Park, J. W. Park, S. K. Bae, S. K. Baek, J. H. Baek, B. J. Lee, K. W. Chung, Y. S. Jung, G. J. Cheon, W. B. Kim, J. H. Chung, Y. S. Rho, "2016 Revised Korean Thyroid Association Management Guidelines for Patient with Thyroid Nodules and Thyroid Cancer." Int J Thyroidol, Vol. 9, No. 2, pp. 59-126, 2016.
DOI
|
6 |
S. G. Park. "Effective Half-life of I-131 in Patients with Differentiated Thyroid Cancer Treated by Radioactive I-131." The Korea Society of Nuclear Medicine, Vol. 42, No. 6, pp. 464-468, 2008.
|
7 |
S. G. Park. "Suggestion of A Practical Simple Calculation Method for Safe Transportation Time after Radioactive Iodine Treatment in Patients with Thyroid Cancer." Journal of the Korea Academia - Industrial cooperaion Society,Vol. 16, No. 6, pp. 3919-25, 2015.
DOI
|
8 |
D. L. North, D. R. Shearer, J. V. Hennessey, G. L. Donovan. "Effective half-life of 131I in thyroid cancer patients." The radiation safety journal Health Physics Vol. 81, No. 3, pp. 325-9, 2001.
|
9 |
C.D. Venencia, A.G Germanier, S.R. Bustos, A.A. Giovannini, E.P. Wyse."Hospital discharge of patient with thyroid carcinoma treated with 131I." The Journal of Nuclear Medicine, Vol. 43, No. 1, pp. 61-5, 2002.
|
10 |
U. Mallick, C. Harmer, B. J. Wadsley, S. Clarke, L. Moss, A. Nicol, P. M. Clark, K. Farnell, R. McCready, J. Smellie, J. A. Franklyn, S. John, C. M. Nutti ng, K. Newbold, C. Lemon, G. Gerrard, A. Abdel-Hamid, J. Hardman, E. Macias, T. Roques, S. Whitaker, R. Vijayan, P. Alvarez, S. Beare, S. Forsyth, L. Kadalayil, A. Hackshaw, "Ablation with low-dose radioio dine and thyrotropin alfa in thyroid cancer." The new england journal of medicine, Vol. 366, No. 18, pp. 1674-85, 2012.
DOI
|
11 |
H. Remy, I. Borget, S. Leboulleux, N. Guilabert, F. Lavielle, J. Garsi, C. Bournaud, S. Gupta, M. Schlumberger, and M. Ricard. "131I Effective Half-Life and Dosimetry in Thyroid Cancer Patients Preparing Patients for Radioiodine Treatment: Increasing Thyroid Cell Uptake and Accelerating the Excretion of Unbound Radioiodine." The Journal of Nuclear Medicine, Vol. 49, No. 9, pp. 1445-50, 2008.
DOI
|
12 |
M. Schlumberger, B. Catargi, I. Borget, D. Deandreis, S. Zerdoud, B. Bridji, S. Bardet, L. Leenhardt, D. Bastie, C. Schvartz, P. Vera, O. Morel, D. Benisvy C. Bournaud, F. Bonichon, C. Dejax, M. Toubert, S. Leboulleux, M. Ricard, E. Benhamou, "Strategies of radioiodine ablation in patients with low-risk thyroid cancer." The new england journal of medicine, Vol. 366, No. 18, pp. 1663-73, 2012.
DOI
|
13 |
J. D. Lee, M. J. Yun, K. H. Nam, Y. W. Chung, E. Y. Soh, C. S. Park. "Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma." Thyroid, Vol. 20, No. 2, pp. 173-9, 2010.
DOI
|
14 |
Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, et al. "Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study." J Clin Endocrinol Metab, Vol. 91, No. 3, pp. 926-32, 2006.
DOI
|
15 |
M. Matovic, Edited by Dr. Thomas J. Fahey, "Preparing Patients for Radioiodine Treatment: Increasing Thyroid Cell Uptake and Accelerating the Excretion of Unbound Radioiodine." Updates in the Understanding and Management of Thyroid Cancer (InTech), pp. 306, 2012.
|